| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SRPK2 |
| Uniprot No | P78362 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-688aa |
| 氨基酸序列 | MSVNSEKSSS SERPEPQQKA PLVPPPPPPP PPPPPPLPDP TPPEPEEEIL GSDDEEQEDP ADYCKGGYHP VKIGDLFNGR YHVIRKLGWG HFSTVWLCWD MQGKRFVAMK VVKSAQHYTE TALDEIKLLK CVRESDPSDP NKDMVVQLID DFKISGMNGI HVCMVFEVLG HHLLKWIIKS NYQGLPVRCV KSIIRQVLQG LDYLHSKCKI IHTDIKPENI LMCVDDAYVR RMAAEATEWQ KAGAPPPSGS AVSTAPQQKP IGKISKNKKK KLKKKQKRQA ELLEKRLQEI EELEREAERK IIEENITSAA PSNDQDGEYC PEVKLKTTGL EEAAEAETAK DNGEAEDQEE KEDAEKENIE KDEDDVDQEL ANIDPTWIES PKTNGHIENG PFSLEQQLDD EDDDEEDCPN PEEYNLDEPN AESDYTYSSS YEQFNGELPN GRHKIPESQF PEFSTSLFSG SLEPVACGSV LSEGSPLTEQ EESSPSHDRS RTVSASSTGD LPKAKTRAAD LLVNPLDPRN ADKIRVKIAD LGNACWVHKH FTEDIQTRQY RSIEVLIGAG YSTPADIWST ACMAFELATG DYLFEPHSGE DYSRDEDHIA HIIELLGSIP RHFALSGKYS REFFNRRGEL RHITKLKPWS LFDVLVEKYG WPHEDAAQFT DFLIPMLEMV PEKRASAGEC LRHPWLNS |
| 预测分子量 | 77,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SRPK2重组蛋白的相关文献摘要信息，供参考：
1. **文献名称**: *Structural basis of SRPK kinase activity toward the SRSF splicing factors*
**作者**: Ngo et al.
**摘要**: 本研究解析了重组人源SRPK2蛋白与剪接因子SRSF1复合物的晶体结构，阐明了SRPK2通过底物结合口袋识别SRSF蛋白精氨酸/丝氨酸结构域(RS domain)的磷酸化机制，并揭示了其催化活性调控的关键氨基酸位点。
2. **文献名称**: *Expression and purification of active SRPK2 using a bacterial system for kinase screening*
**作者**: Wang et al.
**摘要**: 报道了通过大肠杆菌表达系统高效制备重组SRPK2激酶的方法，优化了可溶性表达条件，并通过体外激酶实验验证其活性，为基于SRPK2的高通量抑制剂筛选提供了技术基础。
3. **文献名称**: *SRPK2 accelerates tau phosphorylation and regulates neuronal apoptosis in Alzheimer's disease models*
**作者**: Li et al.
**摘要**: 利用重组SRPK2蛋白处理神经元细胞，发现其通过磷酸化Tau蛋白的特定丝氨酸位点促进神经纤维缠结形成，并激活caspase-3通路，揭示了SRPK2在阿尔茨海默病病理中的潜在作用。
备注：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核对具体文献的准确性。如需更近期研究，可关注2020年后发表的SRPK2功能与结构解析相关论文。
Serine/arginine-rich protein kinase 2 (SRPK2) is a member of the SRPK family that plays a critical role in regulating pre-mRNA splicing by phosphorylating serine/arginine (SR)-rich splicing factors. These SR proteins are essential for spliceosome assembly and alternative splicing, a process generating diverse mRNA isoforms from a single gene. SRPK2. encoded by the SRPK2 gene in humans, is structurally characterized by a conserved bipartite kinase domain and a unique spacer region that modulates substrate specificity and subcellular localization. Unlike its paralog SRPK1. SRPK2 shows enriched expression in the brain and has been implicated in neuronal development and synaptic plasticity.
Recombinant SRPK2 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cell lines) to enable biochemical and functional studies. This engineered protein retains kinase activity, allowing researchers to investigate its phosphorylation mechanisms, substrate interactions, and regulatory roles in splicing. Recombinant SRPK2 has become a key tool for structural analyses (e.g., X-ray crystallography) to map catalytic domains and develop inhibitors. Studies using this protein have revealed its involvement in cell cycle regulation, chromatin remodeling, and stress responses through spliceosome-independent pathways.
Dysregulation of SRPK2 is linked to neurological disorders (e.g., Alzheimer’s disease) and cancers, where aberrant splicing contributes to pathogenesis. Recombinant SRPK2 facilitates drug discovery efforts targeting splicing-related diseases, with recent studies exploring ATP-competitive inhibitors and allosteric modulators. Its role in tau phosphorylation and amyloid-beta toxicity further highlights therapeutic potential in neurodegeneration. Ongoing research leverages recombinant SRPK2 to decode its non-canonical functions and validate clinical biomarkers, positioning it as a multifaceted regulator in cellular physiology and disease.
×
